Fangda Partners
Client SatisfactionThe broad offering at Fangda Partners encompasses both public and private buyouts and co-investments; the group regularly acts for both Chinese and international sponsors. Colin Law leads the team with his expertise in tech, healthcare, and biotech transactions, displaying particular expertise in takeovers of public companies. Raymond Chan is a key name for strategic investments, acquisitions, and joint ventures. Tianyi Chen is noted for his broad knowledge of going-private transactions and cross-border M&A, often advising investment banks and corporations.
Testimonials
Collated independently by Legal 500 research team.
‘Xiaotong Jia is a highly professional lawyer who can respond to clients' questions and needs in a timely manner, and solve clients' problems from a business perspective.’
Key clients
- PAG Asia Capital
- Highlight Capital
- CNCE Group (Hong Kong) Co., Limited中化工装备（香港）有限公司
- CNCE Industrial Group (Hong Kong) Co., Limited 中国化工装备工业集团（香港）有限公司
- Eyebright Medical Technology (Beijing) Co., Ltd.
- China Travel International Investment Hong Kong Limited
- Seazen Group Limited
- NWTN Inc.
- Alma Lasers Ltd
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Alibaba Group
Work highlights
- Advised PAG on an investment agreement with Dalian Wanda Group. PAG and other investors will reinvest in Zhuhai Wanda using funds redeemed from Dalian Wanda Group.
- Represented Highlight Capital in its equity investment in Viva Biotech (Shanghai) Ltd. The transactions involved strategic investors, including HLC Temasek and True Light, with investments totaling approx. US$150 million in Viva Shanghai andUS$60 million through convertible bonds issued by Viva Holdings.
- Represented Mindray in its strategic acquisition of a controlling shareholding right in APT Medical Inc., a listed company on the STAR Market Board. Mindray will acquire 24.61% if APT's shares through its subsidiary SMT for approx. RMB 6.65 billion.
Practice head
The lawyer(s) leading their teams.
Colin Law